Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds

The change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from

June 21, 2024

Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy

What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213 million? And is Adam an optimist? We talk about all

August 29, 2024

Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more

Top of the morning to you, and a fine one it is. Clear blue skies and cool breezes are currently enveloping the placid Pharmalot campus,

April 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.